Related Experiment Videos

FOXM1 downregulation contributes to sevoflurane-induced microglial dysfunction via transcriptional downregulation of

Chen Zhang1, Xiufeng Liu1, Juan Liu2

  • 1Department of Anesthesiology, Beijing Chaoyang Hospital, Capital Medical University, No 8, Gongtinan Road, Chaoyang District, Beijing, 100020, China.

Insights

Forkhead box M1 (FOXM1) protects against sevoflurane-induced cognitive dysfunction by regulating microglial polarization. FOXM1 targets RGS10, reducing inflammation and oxidative stress for better patient outcomes.

Area of Science:

  • Neuroscience
  • Immunology
  • Anesthesiology

Background:

  • Postoperative cognitive dysfunction (POCD) is a common complication following anesthesia.
  • Imbalance in microglial M1/M2 polarization is implicated in POCD development.
  • The role of Forkhead box M1 (FOXM1) in sevoflurane (SEV)-induced microglial polarization is unclear.

Purpose of the Study:

  • To investigate the effect of FOXM1 on SEV-induced microglial M1/M2 polarization.
  • To elucidate the underlying mechanism of FOXM1 in regulating microglial function.
  • To identify potential therapeutic targets for POCD.

Main Methods:

  • Quantitative real-time PCR and Western blot for gene and protein expression.
  • Flow cytometry for microglial M1/M2 marker analysis.
  • ELISA for inflammatory factors, oxidative stress assays, and bioinformatic analyses.
  • ChIP and dual-luciferase reporter assays to confirm FOXM1-RGS10 interaction.

Main Results:

  • SEV significantly decreased FOXM1 expression in HMC3 cells.
  • FOXM1 overexpression ameliorated SEV-induced M1/M2 polarization imbalance, inflammation, and oxidative stress.
  • FOXM1 directly bound to the RGS10 promoter, enhancing its transcription.
  • RGS10 silencing reversed the protective effects of FOXM1.

Conclusions:

  • The FOXM1-RGS10 axis is critical in modulating SEV-induced microglial dysfunction.
  • FOXM1 plays a protective role against SEV-induced POCD by regulating microglial polarization and inflammatory responses.
  • Targeting the FOXM1-RGS10 pathway may offer a novel therapeutic strategy for POCD.